Erratum (DOI:10.1016/j.juro.2009.10.006);Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation

Journal of Urology

Volumn 183, Issue 2, 2010, Pages 546-551

  Stock, Richard G ^a   Yamalachi, Swati ^a   Hall, Simon J ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

androgen antagonists; brachytherapy; prostate; prostatic neoplasms; radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMPOTENCE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; URINE RETENTION;

EID: 73749083585     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.02.2334     Document Type: Erratum

References (19)

1. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360 (2002) 103
2. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 6 (2005) 841
3. Pilepich M.V., Winter K., John M., et al. Phase III Radiation Therapy Oncology group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Boil Phys 50 (2001) 1243
4. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285
5. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292 (2004) 821
6. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post treatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527
7. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352
8. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67
9. Stone N.N., Potter L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472
10. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219
11. Roach III M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer; recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965
12. Norusis M.J. SPSS 10.0 Guide to Data Analysis (2000) Upper Saddle River: Prentice-Hall
13. Stock R.G., Stone N.N., and Iannuzzi C. Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 35 (1996) 267
14. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18 (2000) 1187
15. Ash D., Al-Qaisieh B., Bottomley D., et al. The impact of hormone therapy on post-implant dosimetry and outcome following I-125 implant monotherapy for localized prostate cancer. Radiother Oncol 75 (2005) 303
16. Lee L.N., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444
17. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110 (2007) 551
18. Merrick G.S., Butler W.M., Galbreath R.W., et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk features?. BJU Int 91 (2003) 23
19. Martinez A., Galalae R., Gonzalez J., et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol 170 (2003) 2296